All the news Showing 10 of 33 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources A Big, Fatty Opportunity for Big Pharma Wall Street Journal / 18 January 2019 Take Home from NASH-TAG: On the precipice of the fatty liver pipeline Healio / 18 January 2019 Aramchol reduces liver fat in people with NASH Liz Highleyman / 02 January 2019 A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ... Lean people can develop fatty liver disease Liz Highleyman / 17 December 2018 Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ... Why has liver disease in Britain reached 'almost epidemic' proportions? Daily Telegraph / 17 December 2018 Burden of severe liver disease due to fatty liver will more than double by 2030 Keith Alcorn / 07 December 2018 If current trends in obesity and diabetes continue, at least 520 million people will be living with non-alcoholic fatty liver disease (NAFLD) in western Europe, China, Japan and the United States by ... Thyroid hormone receptor agonists reduce liver fat in people with NAFLD Liz Highleyman / 29 November 2018 Thyroid hormone activation appears to be a promising approach for treating fatty liver disease, according to a pair of studies presented at the AASLD Liver Meeting this month in San Francisco. Two thyroid ... Novel Thyroid Beta Receptor Agonist Cut LDL-C in NAFLD Patients MedPage Today Gastroenterology / 14 November 2018 People with fatty liver disease are at greater risk for multiple cancers Liz Highleyman / 12 November 2018 People with non-alcoholic fatty liver disease (NAFLD) were found to have higher rates of cancer, with the greatest increase observed for gastrointestinal cancers, according to findings presented yesterday at the 2018 AASLD Liver ... Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis Cirius Therapeutics press release / 26 October 2018 ← First123...4Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds